Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression-Reference-Cited by-同舟云学术

Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression

Published:2017-08 Issue:8 Volume:27 Page:714-731
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Ricken Roland,Ulrich Sven,Schlattmann Peter,Adli Mazda

Funder

German Ministry of Education and Research (BMBF)

German Science Foundation (DFG)

European Union

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology

Reference155 articles.

1. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study;Adli;J. Clin. Psychiatry,2002

2. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression;Adli;Pharmacopsychiatry,2008

3. Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II?;Akiskal;J. Affect. Disord.,2005

4. American Psychiatric Association (APA), 2010. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Retrieved from: 〈http://psychiatryonline.org/guidelines〉 (March 16th 2015).

5. High dose tranylcypromine therapy for refractory depression;Amsterdam;Pharmacopsychiatry,1989

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression;Acta Psychiatrica Scandinavica;2024-09-03

2. Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-09

3. Nanocarrier drug delivery system: promising platform for targeted depression therapy;Frontiers in Pharmacology;2024-07-25

4. Plasma Concentrations of Tranylcypromine in Depressed Patients With Chronic Kidney Disease;Journal of Clinical Psychopharmacology;2024-04-18

5. TRANYLCYPROMINE;Prescriber's Guide;2024-04-18